

Heller Ehman White & McAuliffe LLP
Attorney Docket No. 37794-0032

U.S. Serial No. 09/986,344
Peter Law.

Amendment to the Specification

Amend the paragraph on page 13, lines 27 to 41 by insertion of "—, now abandoned—" as shown below.

In accordance with one embodiment of the invention, fusion of the transduced myoblasts is facilitated by administration of large chondroitin-6-sulfate proteoglycan (LCSP) as described in the above-cited U.S. application Serial No. 08/477,377, now abandoned. Trauma from injecting myoblasts into the extracellular matrix triggers the release of basic fibroblast growth factor and large chondroitin-6-sulfate proteoglycan. These released molecules stimulate myoblast proliferation. Increasing the level of large chondroitin-6-sulfate proteoglycan at the injection site facilitates myoblast fusion and proliferation. According,, in accordance with one emb odiment of the invention, large chondroitin-6-sulfate proteoglycan preferably is administered with the transduced myoblasts.